HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 16 (3) , e147-e152
Abstract
No abstract availableKeywords
Funding Information
- Asan Institute for Life Science (2015-656)
- National Cancer Center
- Ministry of Health and Welfare and Family Affairs (HI06C0868)
This publication has 28 references indexed in Scilit:
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Towards a pan-European consensus on the treatment of patients with colorectal liver metastasesEuropean Journal of Cancer, 2006
- HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancerJournal of Clinical Pathology, 2006